TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17135583

Group type: EXPERIMENTAL
Intervention: Episodic use of antiretroviral therapy (drug conservation group)
Number of subjects: 5472

Group type: COMPARATOR
Intervention: Continuous use of antiretroviral therapy (viral suppression group)
Number of subjects: 5472
Study: 14531495

Group type: EXPERIMENTAL
Intervention: Routine chest X-ray
Number of subjects: 472

Group type: COMPARATOR
Intervention: Spontaneous chest X-ray
Number of subjects: 472
Study: 10903018

Group type: EXPERIMENTAL
Intervention: 0.2% tenoxicam-impregnated gauze pack
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.9% saline-impregnated gauze pack
Number of subjects: 80
Study: 8835583

Group type: EXPERIMENTAL
Intervention: Intranasal administration of rifampicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral administration of rifampicin
Number of subjects: 0
Study: 1418170

Group type: EXPERIMENTAL
Intervention: Factory noise at 60, 70, and 80 dB (A)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Construction noise at 60, 70, and 80 dB (A)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Music at 70 dB (A)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sound noise at 70 dB (A)
Number of subjects: 16
Study: 6386749

Group type: EXPERIMENTAL
Intervention: autogenic relaxation training followed by stress-coping training
Number of subjects: 21

Group type: COMPARATOR
Intervention: autogenic relaxation training followed by stress-coping training supplemented with thermal feedback
Number of subjects: 21
Study: 31359830

Group type: EXPERIMENTAL
Intervention: Abstract images
Number of subjects: 402

Group type: COMPARATOR
Intervention: Concrete images
Number of subjects: 402
Study: 28126684

Group type: EXPERIMENTAL
Intervention: Syringe exchange programs (SEPs) with database linkages
Number of subjects: 235
Study: 26328056

Group type: EXPERIMENTAL
Intervention: rBet v 1-FV
Number of subjects: 51

Group type: COMPARATOR
Intervention: Native extract
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study: 23602244

Group type: EXPERIMENTAL
Intervention: Iron supplementation (37.4 mg of elemental iron daily for 12 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 40
Study: 21747102

Group type: COMPARATOR
Intervention: No pills
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Blinded to placebo
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Blinded to echinacea
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Open-label echinacea
Number of subjects: 719

Group type: COMPARATOR
Intervention: Blinded to placebo vs No pills
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Blinded to echinacea vs Open-label echinacea
Number of subjects: 719

Group type: COMPARATOR
Intervention: Subgroup (rated echinacea's effectiveness >50) - Blinded to placebo vs No pills
Number of subjects: 719
Study: 19456878

Group type: EXPERIMENTAL
Intervention: rizatriptan 10 mg
Number of subjects: 146

Group type: COMPARATOR
Intervention: almotriptan 12.5 mg
Number of subjects: 146
Study: 16687642

Group type: EXPERIMENTAL
Intervention: Outreach placement
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (traditional dental school-based clinical experience)
Number of subjects: 49
Study: 15611510

Group type: EXPERIMENTAL
Intervention: Doxorubicin 60 mg/m² plus paclitaxel 200 mg/m² (AP)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² (AC)
Number of subjects: 200
Study: 11426769

Group type: EXPERIMENTAL
Intervention: Bovine heparin
Number of subjects: 98

Group type: COMPARATOR
Intervention: Porcine heparin
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Bovine and porcine heparin
Number of subjects: 98
Study: 9722808

Group type: EXPERIMENTAL
Intervention: Enhanced intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 100
Study: 7744133

Group type: EXPERIMENTAL
Intervention: Diclofenac/misoprostol (50 mg/200 mcg) administered BID or TID (n = 177)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Diclofenac/placebo (50 mg) administered BID or TID (n = 169)
Number of subjects: 346
Study: 2607914

Group type: EXPERIMENTAL
Intervention: Warm irrigating fluids (temperature between 25.5 degrees C and 33 degrees C)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ambient temperature irrigating fluids (temperature between 21.5 and 23 degrees C)
Number of subjects: 24
Study: 4936538

Group type: EXPERIMENTAL
Intervention: Maintenance therapy with phenothiazines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29570121

Group type: EXPERIMENTAL
Intervention: Total Disc Replacement (TDR)
Number of subjects: 175
Study: 28912193

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention including smartphone application (EVIDENT II), five heart-healthy walks, and diet education group session for 3 months
Number of subjects: 200
Study: 26656911

Group type: EXPERIMENTAL
Intervention: Ammonium Chloride (ACID)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Calcium Carbonate (PLA)
Number of subjects: 8
Study: 22243938

Group type: EXPERIMENTAL
Intervention: Hypertonic saline solution (HSS) 100mL (NaCl 7.5%) twice daily for three days
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Hypertonic saline solution (HSS)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 21425566

Group type: EXPERIMENTAL
Intervention: CM plus SJZD
Number of subjects: 45

Group type: COMPARATOR
Intervention: CM alone (Control)
Number of subjects: 45
Study: 18838979

Group type: EXPERIMENTAL
Intervention: High-Ca diet (2300 mg Ca per d)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Low-Ca diet (700 mg Ca per d)
Number of subjects: 11
Study: 16476409

Group type: EXPERIMENTAL
Intervention: BPD patients with major depression (MD)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: BPD patients without major depression (MD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: BPD patients
Number of subjects: 50
Study: 12705061

Group type: EXPERIMENTAL
Intervention: Selective cyclooxygenase-2 inhibitors (e.g., celecoxib, rofecoxib, parecoxib)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classic non-steroidal anti-inflammatory drugs (e.g., ibuprofen, naproxen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valdecoxib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parecoxib
Number of subjects: 0
Study: 11777093

Group type: EXPERIMENTAL
Intervention: Individualized balance training programme (experimental group)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Individualized extra attention programme (control group)
Number of subjects: 94
Study: 9253571

Group type: EXPERIMENTAL
Intervention: Controlled release diclofenac sodium
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 8292679

Group type: EXPERIMENTAL
Intervention: Bilateral ECT
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Unilateral ECT at 2.25 T
Number of subjects: 19

Group type: COMPARATOR
Intervention: Unilateral ECT at barely suprathreshold stimuli
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Higher dosage (2.25 T)
Number of subjects: 19
Study: 2853164

Group type: EXPERIMENTAL
Intervention: Granular porous hydroxylapatite implants
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Solid porous hydroxylapatite implants
Number of subjects: 10
Study: 31490817

Group type: EXPERIMENTAL
Intervention: Propofol at 1 µg/mL (group P1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol at 2 µg/mL (group P2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol at 3 µg/mL (group P3)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol (1 to 3 µg/mL)
Number of subjects: 40
Study: 29788248

Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 1731

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1731
Study: 28708421

Group type: EXPERIMENTAL
Intervention: Conservative fluid management
Number of subjects: 858

Group type: COMPARATOR
Intervention: Liberal fluid management
Number of subjects: 858
Study: 25200901

Group type: EXPERIMENTAL
Intervention: Eye tracker software
Number of subjects: 33

Group type: COMPARATOR
Intervention: Traditional didactic format
Number of subjects: 33
Study: 22248760

Group type: EXPERIMENTAL
Intervention: Epidural S(+)-ketamine with 0.25% bupivacaine (13 mL + 25 mg) before incision
Number of subjects: 29

Group type: COMPARATOR
Intervention: Saline solution before incision followed by epidural S(+)-ketamine with 0.25% bupivacaine (13 mL + 25 mg) after incision
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Epidural S(+)-ketamine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 29
Study: 19479454

Group type: EXPERIMENTAL
Intervention: SPC-flakes
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control cereals
Number of subjects: 51
Study: 17487638

Group type: EXPERIMENTAL
Intervention: Mobile phone reminders programmed to prompt target behaviours
Number of subjects: 5
Study: 16284537

Group type: EXPERIMENTAL
Intervention: Preventive HIV vaccine trial
Number of subjects: 363
Study: 12190904

Group type: EXPERIMENTAL
Intervention: Conventional technique plus synthetic bioactive resorbable graft (OsteoGen) and GoreTex membrane (Group C)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Conventional technique plus nonbioabsorbable GoreTex membrane (Group B)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional technique (Group A)
Number of subjects: 28
Study: 9789590

Group type: EXPERIMENTAL
Intervention: Glimepiride, Repaglinide, Glucagon-like peptide I (drugs stimulating insulin secretion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (medications reducing insulin resistance)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vanadium (insulin-mimetic agents)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha glucosidase inhibitors
Number of subjects: 0
Study: 7542114

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no G-CSF)
Number of subjects: 16
Study: 8638061

Group type: EXPERIMENTAL
Intervention: Carbocysteine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 392832

Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATGAM; ATG) for up to 16 weeks in addition to azathioprine and prednisone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no ATG)
Number of subjects: 20
Study: 31924322

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg dual therapy
Number of subjects: 2725

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg dual therapy
Number of subjects: 2725

Group type: COMPARATOR
Intervention: Dabigatran dual therapy
Number of subjects: 2725

Group type: COMPARATOR
Intervention: Warfarin triple therapy
Number of subjects: 2725
Study: 30574802

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001 (6×10^9 cfu)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001
Number of subjects: 474

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis HN019 (9×10^9 cfu)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Children who developed eczema
Number of subjects: 474
Study: 25192771

Group type: EXPERIMENTAL
Intervention: Very low nicotine content (VLNC) cigarettes
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Very low nicotine content (VLNC) cigarettes with lower nicotine yield (0.05 mg)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Co-use of normal nicotine content cigarettes
Number of subjects: 112
Study: 23938046

Group type: EXPERIMENTAL
Intervention: Aerobic Training
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Energy Conservation Management
Number of subjects: 270

Group type: COMPARATOR
Intervention: Low-intensity intervention (control)
Number of subjects: 270
Study: 21333426

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 1445

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1445
Study: 19341987

Group type: EXPERIMENTAL
Intervention: Zinc gluconate 15mg/day capsules
Number of subjects: 40

Group type: COMPARATOR
Intervention: Corn-starch placebo
Number of subjects: 40
Study: 17298975

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 826

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES) in small stents/bypass grafts
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES) in other patients
Number of subjects: 826
Study: 16329082

Group type: EXPERIMENTAL
Intervention: Lichtenstein mesh
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Prolene Hernia System (PHS)
Number of subjects: 300
Study: 12791056

Group type: EXPERIMENTAL
Intervention: Plywood ceiling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synthetic-netting ceiling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insecticide-treated synthetic-netting ceiling (deltamethrin 12.5 mg/m2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plastic insect-screen ceiling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Closed eaves with mud
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control hut
Number of subjects: 0
Study: 10522581

Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5 mg x ml(‐1)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Bupivacaine 5.0 mg x ml(‐1)
Number of subjects: 104
Study: 7794434

Group type: EXPERIMENTAL
Intervention: 3‐in‐1 block
Number of subjects: 280

Group type: COMPARATOR
Intervention: femoral nerve block
Number of subjects: 280
Study: 1723814

Group type: EXPERIMENTAL
Intervention: Alfuzosine 2.5 mg x 3
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 7048251

Group type: EXPERIMENTAL
Intervention: Captopril-labetalol combination treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Captopril alone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Labetalol alone
Number of subjects: 15
Study: 31537504

Group type: EXPERIMENTAL
Intervention: CT angiography at 70 kVp
Number of subjects: 63

Group type: COMPARATOR
Intervention: Dual-energy CT with VMI at 40 keV
Number of subjects: 63
Study: 31242924

Group type: EXPERIMENTAL
Intervention: Integrated risk assessment using HM metascore
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Survival prediction by HM metascore
Number of subjects: 604
Study: 28481335

Group type: EXPERIMENTAL
Intervention: SLIMMER combined dietary and physical activity lifestyle intervention (10-month programme)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Usual healthcare (control group)
Number of subjects: 316
Study: 25278227

Group type: EXPERIMENTAL
Intervention: Nine-valent human papillomavirus vaccine (selected dose formulation)
Number of subjects: 15000

Group type: COMPARATOR
Intervention: Four-valent human papillomavirus vaccine (active control)
Number of subjects: 15000

Group type: COMPARATOR
Intervention: Four-valent human papillomavirus vaccine
Number of subjects: 15000
Study: 23443238

Group type: EXPERIMENTAL
Intervention: 5-day complete dietary replacement (Arm 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Written recommendations to reduce phthalate and BPA exposures (Arm 2)
Number of subjects: 40
Study: 21459791

Group type: EXPERIMENTAL
Intervention: Two intensive courses (trial 9801)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: One intensive course (trial 9803)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Six outpatient courses (trial 9803)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Overall survival after complete remission (planned post-remission courses)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Favorable or normal karyotype (n=97)
Number of subjects: 211
Study: 18645509

Group type: EXPERIMENTAL
Intervention: m-DOT
Number of subjects: 234
Study: 16776928

Group type: EXPERIMENTAL
Intervention: Midazolam (7.5 ‐ 15 mg before sleep, n = 113)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Estazolam (1 ‐ 2 mg before sleep, n = 104)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 217

Group type: COMPARATOR
Intervention: Estazolam
Number of subjects: 217
Study: 12631045

Group type: EXPERIMENTAL
Intervention: BIS monitored desflurane anesthesia
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: BIS monitored propofol anesthesia
Number of subjects: 160

Group type: COMPARATOR
Intervention: Non-monitored desflurane anesthesia
Number of subjects: 160

Group type: COMPARATOR
Intervention: Non-monitored propofol anesthesia
Number of subjects: 160
Study: 10856535

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Atorvastatin 120 mg/day
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Atorvastatin 160 mg/day
Number of subjects: 35
Study: 9021345

Group type: EXPERIMENTAL
Intervention: Agnus castus extract (BP1095E1) 120 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Agnus castus extract (BP1095E1) 240 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Agnus castus extract (BP1095E1) 480 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1392436

Group type: EXPERIMENTAL
Intervention: U40 Velasulin (15 IU)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: U100 Velasulin (15 IU)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: U40 Insulatard (20 IU)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: U100 Insulatard (20 IU)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: U40 Mixtard (20 IU)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: U100 Mixtard (20 IU)
Number of subjects: 18
Study: 3882735

Group type: EXPERIMENTAL
Intervention: Verapamil (320 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28891027

Group type: EXPERIMENTAL
Intervention: Zinc sulfate monohydrate 3 mg/kg twice a day orally for 10 days along with standard antibiotics
Number of subjects: 18

Group type: COMPARATOR
Intervention: No zinc (antibiotic treatment only)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Zinc sulfate supplementation
Number of subjects: 18
Study: 27855872

Group type: EXPERIMENTAL
Intervention: Behaviour change intervention (clinic events, community events, and radio messaging) for 6 months
Number of subjects: 306

Group type: COMPARATOR
Intervention: Standard care control for 6 months
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Behaviour change intervention (with coverage greater than 35%)
Number of subjects: 306
Study: 24095088

Group type: EXPERIMENTAL
Intervention: Pharmacist consultations in primary care clinics
Number of subjects: 82
Study: 22094451

Group type: EXPERIMENTAL
Intervention: Endoscopic ablation system (EAS)
Number of subjects: 51
Study: 20798191

Group type: EXPERIMENTAL
Intervention: Sunscreen with SPF 60 applied twice a day for 28 days
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 18687989

Group type: EXPERIMENTAL
Intervention: NdFeB magnet device
Number of subjects: 45

Group type: COMPARATOR
Intervention: Dental floss
Number of subjects: 45

Group type: COMPARATOR
Intervention: Transfer tray
Number of subjects: 45
Study: 16983914

Group type: EXPERIMENTAL
Intervention: Shenmai Injection (SMI) 30 ml once a day for 10 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional therapy plus NPPV (Control)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Shenmai Injection (SMI)
Number of subjects: 48
Study: 12906185

Group type: EXPERIMENTAL
Intervention: ECG-gated spiral CT using MSCT scanners
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary artery motion measurement
Number of subjects: 0
Study: 12452216

Group type: EXPERIMENTAL
Intervention: Sufentanil 1 microg/kg (Group I)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl 2 microg/kg (Group II)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.5 microg/kg administered prior to skin incision, median sternotomy, CPB, and after coming off CPB
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl 1 mg/kg administered at the same time periods as sufentanil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sufentanil group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sufentanil and Fentanyl
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 60
Study: 10626336

Group type: EXPERIMENTAL
Intervention: Movalis 7.5 mg
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Movalis 15 mg
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Movalis (dose increased from 7.5 mg to 15 mg in poor responders)
Number of subjects: 630
Study: 7732154

Group type: EXPERIMENTAL
Intervention: Social support (together condition)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Social support (together condition) in high stress
Number of subjects: 26

Group type: COMPARATOR
Intervention: Social support (alone condition)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: High stress condition
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Low stress condition
Number of subjects: 26
Study: 1981434

Group type: EXPERIMENTAL
Intervention: Active grenz ray therapy (4 Gy, 10 kV, applied 6 times at 1-week intervals)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Stimulated therapy (control)
Number of subjects: 15
Study: 6757467

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette‐Guerin (BCG) immunotherapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study: 30723114

Group type: EXPERIMENTAL
Intervention: Whole genome-derived tiled peptide arrays
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Mass spectrometry analysis
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Tiled peptide arrays
Number of subjects: 172
Study: 27766712

Group type: EXPERIMENTAL
Intervention: 0.5% chlorhexidine gluconate in GIC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 100% aqueous miswak in GIC
Number of subjects: 60

Group type: COMPARATOR
Intervention: Deionized water in GIC (control)
Number of subjects: 60